Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial

Cikes, M. et al. (2022) Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure, 10(5), pp. 336-346. (doi: 10.1016/j.jchf.2022.01.018) (PMID:35483796)

[img] Text
268900.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Objectives: In this study, we sought to assess the relationship between AFF and outcomes, the treatment response to sacubitril/valsartan and first-detected AFF in patients with HFpEF enrolled in the PARAGON-HF trial. Background: Atrial fibrillation and flutter (AFF) are common in heart failure with preserved ejection fraction (HFpEF) and increase the risk of adverse outcomes. Methods: A total of 4,776 patients formed 3 groups: those with AFF according to electrocardiography (ECG) at enrollment (n = 1,552; 33%), those with history of AFF but without AFF on ECG at enrollment (n = 1,005; 21%), and those without history of AFF or AFF on ECG at enrollment (n = 2,219, 46%). We assessed outcomes, treatment response to sacubitril/valsartan in each group, and the risk associated with first-detected AFF in patients without any known AFF. The primary outcome was a composite of total heart failure hospitalizations and cardiovascular death. Results: History of AFF and AFF at enrollment were associated with higher risk of the primary outcome (risk ratio [RR]: 1.36 [95% CI: 1.12-1.65] and RR 1.31 [1.11-1.54], respectively), than no AFF. Neither history of AFF nor AFF at enrollment modified the treatment effect of sacubitril/valsartan. Post randomization AFF occurred in 12% of patients without previous AFF and was associated with 2.8-fold higher risk of the primary outcome, but it was not influenced by sacubitril/valsartan. Conclusions: History of AFF and AFF on ECG at enrollment were associated with a higher risk of the primary outcome. First-detected AFF was not influenced by sacubitril/valsartan, yet it was associated with increased risk of all subsequent outcomes and may represent a potential target for future HFpEF trials. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).

Item Type:Articles
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Cikes, M., Planinc, I., Claggett, B., Cunningham, J., Milicic, D., Sweitzer, N., Senni, M., Gori, M., Linssen, G., Shah, S. J., Packer, M., Pfeffer, M., Zile, M. R., Anand, I., Chiang, L.-M., Lam, C. S.P., Redfield, M., Desai, A. S., McMurray, J. J.V., and Solomon, S. D.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:JACC: Heart Failure
ISSN (Online):2213-1787
Published Online:06 April 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in JACC: Heart Failure 10(5): 336-346
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record